Imaging & Physiology Summit

RCT to Compare Maximum Hyperemic Effect of Single i.v. Bolus Regadenoson to Central venous Infusion of Adenosine

Seoul, Korea, december 7th, 2013



Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands



Background

- Maximum coronary hyperemia is mandatory for correct decision making with respect to revascularization in the catheterization laboratory
- (Central venous) Adenosine is the present gold standard to induce maximum coronary hyperemia
 - Reliable, safe, well investigated & reproducible
 - In some centres, the non-trivial preparation, high price and need for central venous access may be a barrier
- Regadenoson is a selective A_{2A} receptor agonist
 - Single bolus, non-weight based injection
 - Only limited data available with respect to efficacy, reproducibility, safety and ways of administration


Aims of this Study

- To investigate if the hyperemic effect of *single bolus regadenoson injection* is equal to the present gold standard (i.e. *central venous adenosine infusion*)
- To determine *time intervals* to onset of maximum hyperemia and the *duration of steady state hyperemia* after single bolus regadenoson injection
- To compare *central venous versus peripheral venous* single bolus administration of regadenoson
- To investigate side-effects as well as safety of repeated regadenoson injections

Population & Methods

- 100 patients scheduled for measurement of FFR (diagnostic and/or interventional procedures)
- Pa measured by guiding catheter
- Pd measured by 0.014 PressureWire (St. Jude Medical)
- Central venous line for *adenosine infusion* (140 μg/kg/min) or central venous regadenoson injection (single bolus 400 μg)
- Peripheral venous access for peripheral venous *regadenoson* injection (single bolus of400 µg)
- Randomization with respect to regadenoson central / central (N=25) peripheral / central (N=25) central / peripheral (N=25) peripheral / peripheral (N=25)

Adenosine (central venous infusion) vs single bolus of Regadenoson for maximum hyperemia (N=100)




randomization with respect to regadenoson: *central/central (N=25) peripheral/central(N=25) central/peripheral (N=25) peripheral/peripheral (N=25)*

Baseline Characteristics


Characteristics	Number/Percentage
Male/female	75 / 25
Age (years)	66 ± 8
Study coronary artery – LM	7
– LAD – CX	54 20
– CX – RCA	20 19
Diameter (mm)	3.2 ± 0.6
Stenosis percentage - 30-50% - 50-70% - 70-90% - >90%	35 38 21 6
Fractional Flow Reserve	0.75 ± 0.10
Interventional procedure	54


distribution of coronary artery



stenosis percentage >90 70-90 30-50 50-70 N= 100 0-50 % : 35 50-70 % : 38 70-90 % : 21

> 90 %: 6






62 central 0,66 venous FFR adenosine Infusion 140 µg/kg/min

> Single bolus Peripheral **Injection of** 400 µg of regadenoson


FFR

ESET




peripheral single bolus injection of 400 µg of regadenoson

Regadenoson vs Adenosine (N=100)



- Mean Difference 0.00 ± 0.01
- In only 3 patients difference > 0.02
- No patient in whom decision changed


Central & Peripheral Regadenoson



• Mean Difference 0.00 ± 0.02

Mean Difference 0.00 ± 0.01


Reproducibility of Regadenoson (N=87)



• Mean Difference 0.01 \pm 0.02

Duration of Maximum Hyperemia

- In *all* patients, steady state maximum hyperemia was achieved with adenosine and maintained during infusion
- For regadenoson, the hyperemic plateau after single injection ranged from 10 sec – 10 minutes.



Duration of hyperemia

> 30 sec	86%
> 1 min	74%
> 3 min	35%

Safety & Side Effects

- No noticeable side effects were seen with both drugs, except for the well-known chest pain
 - Severity rating 6/10 for adenosine and 4/10 for regadenoson
- In 6 patients, short innocent transient AV-conduction disturbances occurred without necessity to interrupt administration
 - Five times with adenosine only, once with both drugs
- Not any problem occurred with repeated regadenoson injections
- Hemodynamic response to regadenoson was similar to adenosine

Conclusions (1)

- Regadenoson, as a single bolus injection of 400 µg, is an excellent alternative for central venous adenosine infusion to induce maximum hyperemia
 - Rapid onset (< 30 sec) but variable duration
 - No difference between central and peripheral regadenoson
- Useful in many patients with single-vessel disease or focal two-vessel disease
- In complex cases where extensive pressure-pullback recordings are necessary (with more prolonged hyperemia), central venous adenosine remains the drug of choice

Conclusions (2)

 Repeated injections of regadenoson can be performed and are safe

 No noticeable side effects of regadenoson or adenosine, except the harmless chest discomfort

 Finally, steady state hyperemia was achieved in all patients in this study with central venous adenosine, which confirms the role of this drug as gold standard